Robert C Gosselin
Department of Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA
Robert C Gosselin is a recently retired clinical laboratory scientist, with more than 40 years experience in the field of technical hemostasis. For the past 30 years, he has been at the University of California, Davis Health System (UCDHS) as a supervisor, and then transitioned to coagulation specialist in the 1998, where he has served as the sole technologist for this section. While in the capacity of coagulation specialist, Mr. Gosselin has evaluated and implemented a vast number of clinical tests, as well as participated in numerous collaborative studies within UCDHS, as well as industry-sponsored studies. The routine testing have included evaluating and implementing protein C activity testing, lupus anticoagulant testing, euglobulin lysis times, thromboelastography, heparin-induced thrombocytopenia ELISA testing, and others. In addition, for research testing in both animal and humans, he performs testing for more esoteric tests including ADAMTS-13 testing, chromogenic factor XIII activity, thrombin-antithrombin complexes, and prothrombin fragment. For many years Mr. Gosselin collaborated with Dr John Owings, a trauma surgeon, in numerous studies to include hypercoagulablity in critically injured patients, effect of trauma on platelet functions, and microchimerism in transfused trauma patients. In addition, he has collaborated with the clinical staff at the UCD Veterinary hospital for evaluating numerous coagulation studies in dogs, cats, sheep and horses. For industry, Mr. Gosselin has participated in numerous studies for instrument and reagent evaluations (N~50) as part of the sponsor’s pre-submission data collection. His current interest is in the area of the direct oral anticoagulants (DOACs), the methods for measuring or assessing this newer class of anticoagulants and their impact on coagulation testing. For the proposed project, he will aid in the execution and development of in vitro assays to measure blood coagulation properties for the proposed nanoparticles and compounds.